Bristol Myers Squibb Company (NYSE:BMY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Bristol Myers Squibb Company (NYSE:BMY) have earned a consensus rating of “Moderate Buy” from the twenty-five brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation, twelve have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $66.0556.

Several equities analysts have commented on the company. Cantor Fitzgerald reissued a “neutral” rating and set a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Roth Capital initiated coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 target price on the stock. Citigroup reiterated a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Bank of America dropped their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Finally, Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, July 30th.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $63.75 on Thursday. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $68.10. The company has a 50-day simple moving average of $59.27 and a two-hundred day simple moving average of $58.86. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a market capitalization of $130.22 billion, a PE ratio of 14.04, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter last year, the business posted $1.46 EPS. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts anticipate that Bristol Myers Squibb will post 6.96 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several large investors have recently modified their holdings of the stock. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb during the 4th quarter valued at about $25,000. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $25,000. Physician Wealth Advisors Inc. lifted its stake in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares in the last quarter. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $27,000. Finally, Bayban bought a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $31,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers’ newer growth products now generate approximately 56% of revenue. Opdivo Qvantig, Reblozyl and Breyanzi are helping counter generic erosion and could strengthen the company’s growth profile as older drugs face increasing pressure. Is BMY’s Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
• Positive Sentiment: Analysts at Erste Group raised their Bristol Myers 2026 EPS estimate to $6.96 from $6.34 and its 2027 estimate to $6.51 from $6.10, reinforcing expectations for earnings resilience. Bristol Myers Squibb EPS Estimates
• Positive Sentiment: BMY announced a roughly $2.3 billion, 600,000-square-foot manufacturing campus in Houston. The facility will support small molecules, biologics and antibody-drug conjugates, create nearly 500 permanent jobs and expand internal production flexibility through 2030. BMS banks on Texas for $2.3bn multi-modal manufacturing facility
• Neutral Sentiment: A new Phase 4 melanoma immunotherapy study in India expands BMY’s clinical and commercial footprint, although the trial is unlikely to materially affect near-term revenue without additional efficacy or regulatory updates. BMY Expands Melanoma Immunotherapy Footprint With New Phase 4 Trial in India
• Neutral Sentiment: Reports of possible merger discussions between Bristol Myers and AstraZeneca remain unconfirmed. Such a transaction could offer strategic scale, but the lack of confirmation and skepticism from investors make it an uncertain stock catalyst. AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY)
• Negative Sentiment: The Houston project represents a substantial upfront capital commitment. Although it supports long-term manufacturing capacity, investors may weigh the $2.3 billion expenditure against execution risks and near-term returns on investment. BMS Plans $2.3B Houston Manufacturing Campus

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.